A Biomarker Risk Prediction Model for Prostate Cancer
前列腺癌的生物标志物风险预测模型
基本信息
- 批准号:8990468
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-10-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:ANXA2 geneAddressAffectAfrican AmericanAnnexinsAntigensArchivesBenign Prostatic HypertrophyBiologicalBiological MarkersBiopsyBiopsy SpecimenCancer CenterCancer PatientCancer PrognosisCandidate Disease GeneCaucasiansCellsChaperonin 60ChemopreventionClassificationClinicClinicalCommunitiesDetectionDiagnosisDiet and NutritionDiseaseDistrict of ColumbiaEarly DiagnosisEthnic groupExhibitsFutureGene ChipsGene ExpressionGene Expression ProfilingGene ProteinsGenesGleason Grade for Prostate CancerGoalsHeat shock proteinsHeat-Shock Proteins 70HumanImmunohistochemistryIn Situ HybridizationIndolentLogistic ModelsMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMedical centerMethodologyMicroarray AnalysisModelingNewly DiagnosedNormal tissue morphologyOutcomePathologistPathologyPopulationProstateProstate carcinomaProstate-Specific AntigenProteinsPublic HealthRNARaceRecordsResearchRiskSamplingSerine Proteinase InhibitorsSourceSpecimenStaining methodStainsStatistical Data InterpretationStatistical ModelsStratificationSubgroupTestingTherapeuticTissue SampleTissuesTransrectal UltrasoundUltrasonographyUnited States Department of Veterans AffairsUniversitiesUniversity HospitalsVariantWashingtonWestern Worldabstractingcancer health disparitycancer preventioncancer riskclinical applicationcohortdiagnostic screeningdifferential expressiondisease diagnosisgenetic profilinggenetic signaturehigh riskinsightinterestmenmolecular markermortalitynovel therapeuticsoverexpressionpotential biomarkerpredictive markerpredictive modelingprognosticprostate biopsyprotein expressionrectalscreeningspecific biomarkerstooltrendtumor registryurologic
项目摘要
DESCRIPTION (provided by applicant):
Modified Project Summary/Abstract Section African American (AA) men are at a greater risk of developing aggressive prostate cancer (PrCa) than are Caucasian men. Therefore, identifying biomarkers involved in aggressive PrCa that can be used to identify AA men for specific and/or novel therapies would provide a major advance in public health. Consequently, there is intense effort to identify potential biomarkers that could independently predict poor clinical outcome and identify novel therapies for men with aggressive PrCa. Notably, heat shock proteins, PrCa Antigen 3, and Serine Protease Inhibitor Kazal-type 1, are all overexpressed in men with PrCa, where as Annexin II is suppressed. Despite the biological importance of these biomarkers, no studies have yet evaluated the significance of these biomarkers in AA men with aggressive PrCa. We believe that Howard's University Hospital urologic clinic which evaluates approximately 200 PrCa patients per year, is an ideal source for studying the importance of biomarkers as predictors of aggressive PrCa in AA men. We propose to evaluate the bi-directional expression of protein and gene signature pairs different in archival tissue samples from AA men who had been diagnosed with an aggressive form of PrCa at the Washington VA Medical Center and Howard and Johns Hopkins University Cancer Centers. The main hypothesis is that the bi-directional expression of genes and proteins is predictive of aggressive,
lethal PrCa risk. To test this hypothesis we propose two aims. The first aim will test the hypothesis that microarray gene expression profiling produces bi-directional biomarker signature pairs that can be used to build a risk prediction model for PrCa. The second aim will test the hypothesis that the risk prediction of poor clinical outcome with bi-directional gene and protein expression pairs is superior to the use of a single gene or protein. Candidate pairs include those discovered in Aim 1. We anticipate that these studies may provide insight into selected genes and proteins as reliable predictive biomarkers for identifying aggressive PrCa in AA men, and could inform future human clinical applications for treatment of aggressive PrCa.
描述(由申请人提供):
非裔美国人(AA)男性比白人男性患侵袭性前列腺癌(PrCa)的风险更大。因此,鉴定参与侵袭性PrCa的生物标志物,可用于鉴定AA男性的特异性和/或新型治疗,将为公共卫生提供重大进展。因此,有大量的努力,以确定潜在的生物标志物,可以独立地预测不良的临床结果,并确定新的治疗男性与积极的PrCa。值得注意的是,热休克蛋白,PrCa抗原3和丝氨酸蛋白酶抑制剂Kazal-1型,都在PrCa男性中过表达,其中膜联蛋白II被抑制。尽管这些生物标志物具有生物学重要性,但尚未有研究评估这些生物标志物在患有侵袭性PrCa的AA男性中的重要性。我们认为,霍华德大学医院泌尿科诊所每年评估约200例PrCa患者,是研究生物标志物作为AA男性侵袭性PrCa预测因子的重要性的理想来源。我们建议评估双向表达的蛋白质和基因签名对不同的档案组织样本AA男子已被诊断为侵略性形式的PrCa在华盛顿VA医学中心和霍华德和约翰霍普金斯大学癌症中心。主要的假设是基因和蛋白质的双向表达是侵略性的预测,
致命PrCa风险。为了验证这一假设,我们提出了两个目标。第一个目标将测试微阵列基因表达谱产生双向生物标志物签名对的假设,该双向生物标志物签名对可用于构建PrCa的风险预测模型。第二个目标将检验以下假设:用双向基因和蛋白质表达对预测不良临床结果的风险上级使用单个基因或蛋白质。候选对包括在目标1中发现的那些。我们预计,这些研究可能会提供深入了解选定的基因和蛋白质作为可靠的预测生物标志物,用于识别AA男性的侵袭性PrCa,并可能为未来的人类临床应用提供信息,用于治疗侵袭性PrCa。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tamaro Syton Hudson其他文献
Tamaro Syton Hudson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tamaro Syton Hudson', 18)}}的其他基金
A Biomarker Risk Prediction Model for Prostate Cancer
前列腺癌的生物标志物风险预测模型
- 批准号:
8411115 - 财政年份:2012
- 资助金额:
-- - 项目类别:
A Biomarker Risk Prediction Model for Prostate Cancer
前列腺癌的生物标志物风险预测模型
- 批准号:
10063436 - 财政年份:2012
- 资助金额:
-- - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant